800 mg tarenflurbil twice per day was well tolerated for up to 24 months of treatment, with evidence of a dose-related effect on measures of daily activities and global function in patients with mild AD.
We will try to keep you posted when the Phase 3 trial begins. Feel free to subscribe to our email list if you would like to be notified.
